Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19
Monique G.P. van der Wijst, Sara E. Vazquez, George C. Hartoularos, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Science Immunology (2021) Vol. 6, Iss. 62
Open Access | Times Cited: 496
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
Takaki Asano, Bertrand Boisson, Fanny Onodi, et al.
Science Immunology (2021) Vol. 6, Iss. 62
Open Access | Times Cited: 348
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Carly G.K. Ziegler, Vincent N. Miao, Anna H. Owings, et al.
Cell (2021) Vol. 184, Iss. 18, pp. 4713-4733.e22
Open Access | Times Cited: 277
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
Paul Bastard, Elizaveta Orlova, Leila Sozaeva, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 7
Open Access | Times Cited: 253
SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease?
Vanessa Sancho‐Shimizu, Petter Brodin, Aurélie Cobat, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 6
Open Access | Times Cited: 134
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
Jonathan Lopez, Marine Mommert, William Mouton, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 10
Open Access | Times Cited: 118
Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona
Xavier Solanich, Raúl Rigo‐Bonnin, Victor-David Gumucio, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 8, pp. 1733-1744
Open Access | Times Cited: 87
Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1
Christian Meisel, Bengisu Akbil, Tim Meyer, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 14
Open Access | Times Cited: 83
Neutralizing type‐I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19
Michael S. Abers, Lindsey B. Rosen, Ottavia M. Delmonte, et al.
Immunology and Cell Biology (2021) Vol. 99, Iss. 9, pp. 917-921
Open Access | Times Cited: 81
Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
Sara E. Vazquez, Paul Bastard, Kathleen Kelly, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 6, pp. 1169-1171
Open Access | Times Cited: 62
Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor
Oded Danziger, Roosheel S. Patel, Emma J. DeGrace, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 4, pp. e1010464-e1010464
Open Access | Times Cited: 47
Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
Shohei Eto, Yoko Nukui, Miyuki Tsumura, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 7, pp. 1360-1370
Open Access | Times Cited: 37
Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned
Giorgia Bucciol, Stuart G. Tangye, Isabelle Meyts
Current Opinion in Pediatrics (2021) Vol. 33, Iss. 6, pp. 648-656
Open Access | Times Cited: 52
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Donald C. Vinh, Laurent Abel, Paul Bastard, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 7, pp. 1425-1442
Open Access | Times Cited: 40
A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface
Juliette Léon, Daniel A. Michelson, Judith Olejnik, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 119, Iss. 1
Open Access | Times Cited: 29
Understanding the contextual functions of C1q and LAIR-1 and their applications
Myoungsun Son
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 5, pp. 567-572
Open Access | Times Cited: 20
Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients
Leonardo Sorrentino, Matteo Fracella, Federica Frasca, et al.
Microorganisms (2023) Vol. 11, Iss. 3, pp. 689-689
Open Access | Times Cited: 11
LAIR-1 limits macrophage activation in acute inflammatory lung injury
Doumet Georges Helou, Christine Quach, Benjamin P. Hurrell, et al.
Mucosal Immunology (2023) Vol. 16, Iss. 6, pp. 788-800
Open Access | Times Cited: 10
Transcriptional Profiling and Machine Learning Unveil a Concordant Biosignature of Type I Interferon-Inducible Host Response Across Nasal Swab and Pulmonary Tissue for COVID-19 Diagnosis
Cheng Zhang, Yigang Feng, Chiwing Tam, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 23
Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai
Dongling Shi, Jie Chen, Meng Zhao, et al.
Journal of Clinical Immunology (2024) Vol. 44, Iss. 3
Open Access | Times Cited: 2
Immunology of SARS-CoV-2 infections and vaccines
Dominik Schenten, Deepta Bhattacharya
Advances in immunology (2021), pp. 49-97
Open Access | Times Cited: 15
More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients
Candie Joly, Delphine Desjardins, Raphaël Porcher, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study
Fabrice Cognasse, Hind Hamzeh‐Cognasse, Mickaël Rosa, et al.
EBioMedicine (2022) Vol. 87, pp. 104414-104414
Open Access | Times Cited: 7
Phenocopies of Inborn Errors of Immunity
Elena W.Y. Hsieh, Cullen M. Dutmer, Vijaya Knight
(2024), pp. 825-843
Closed Access
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection
Roshan Ghimire, Rakshya Shrestha, Radhika Amaradhi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top